内毒素吸附膜治疗新型冠状病毒肺炎应用研究进展
本文为综述,系统回顾了脓毒症中细胞因子风暴导致病情恶化的既往报告,并分析了重症危重型COVID-19病程中使用内毒素吸附膜治疗患者的疗效。2019新型冠状病毒(2019-nCoV)侵入人体后可刺激免疫系统产生大量细胞因子,触发细胞因子风暴,导致严重感染、急性肺损伤和多器官功能障碍等。作者认为,理论上清除过度产生的细胞因子可避免细胞因子风暴,降低重症危重型COVID-19发生率和严重不良预后。文中进一步提供了内毒素吸附膜治疗COVID-19的有效临床证据。
要点
- 2019-nCoV侵入人体后刺激免疫系统产生大量细胞因子,触发细胞因子风暴,导致严重感染、急性肺损伤、多器官功能障碍等。
- 世界卫生组织于2020年1月12日将新发现的冠状病毒命名为2019-nCoV,其所致疾病命名为COVID-19。
- 作者认为理论上清除过度产生的细胞因子可避免细胞因子风暴,降低重症危重型COVID-19发生率和严重不良预后。
- 作者系统回顾了脓毒症中细胞因子风暴导致病情恶化的既往报告,并分析了重症危重型COVID-19病程中使用内毒素吸附膜治疗患者的疗效。
适用人群与场景
- 重症危重型COVID-19患者(文中分析其病程中使用内毒素吸附膜治疗的疗效)
研究设计与关键结果
- 综述系统回顾了脓毒症中细胞因子风暴导致病情恶化的既往报告。
- 作者分析了重症危重型COVID-19病程中使用内毒素吸附膜治疗患者的疗效,进一步提供内毒素吸附膜治疗COVID-19的有效临床证据。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为理论上清除过度产生的细胞因子可避免细胞因子风暴,降低重症危重型COVID-19发生率和严重不良预后。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The new type coronavirus disease 2019 (COVID-19) is a contagious disease of severe lung inflammation induced by 2019 novel coronavirus (2019-nCoV). The World Health Organization (WHO) nomenclature of the newly discovered coronavirus was 2019-nCoV and the disease caused by 2019-nCoV was named COVID-19 on January 12, 2020. After 2019-nCoV invasion into a human body, it can stimulate the human immune system and engender a large number of cytokines, triggering a cytokine storm, resulting in severe infection, acute lung injury, multiple organ dysfunction, etc. Therefore, theoretically, the removal of over-production of cytokines can avoid the occurrence of cytokine storm and reduce the incidence of severe critical COVID-19 and serious poor prognosis. In this review, the authors systematically reviewed the past published reports related to the occurrence of cytokine storm in sepsis resulting in deterioration of disease situation, and recently they analyzed the therapeutic effects of patients with severe critical COVID-19 using endotoxin adsorption membrane for treatment in the disease course, further providing the effective clinical evidence of applying endotoxin adsorption membrane for treatment of COVID-19.
参考来源
- Jiao J, Buzukela A, Li M, et al. [Advance in research on application of endotoxin adsorption membrane in treatment of coronavirus disease 2019]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35728859. doi:10.3760/cma.j.cn121430-20210803-01120
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。